Biopharma’s nonprofit deal and grant activity continues to settle into a post-pandemic rhythm, with both showing a sustained decline from the elevated levels seen during and even after the COVID-19 era.
Samsung Medical Center spinoff Aimedbio Inc. announced raising ₩51.1 billion (US$37.15 million) in pre-IPO funding to advance its portfolio of clinical and preclinical antibody-drug conjugate (ADC) candidates.
Asian health care-focused private equity firm Quadria Capital announced the final close of its Fund III with $1.07 billion in total commitments to transform health care across Asia, which is expected to drive 40% of global health care growth by 2030.
Samsung Medical Center spinoff Aimedbio Inc. announced raising ₩51.1 billion (US$37.15 million) in pre-IPO funding to advance its portfolio of clinical and preclinical antibody-drug conjugate (ADC) candidates.
Biopharma’s nonprofit deal and grant activity continues to settle into a post-pandemic rhythm, with both showing a sustained decline from the elevated levels seen during and even after the COVID-19 era.
RSS
